Investment in Shanghai Lichi Medical Technology Co., Ltd. and Application of the Equity Method
First written in FY2019-Q3. 1 of 7 entries say "Dropped", first in FY2021-Q2. Latest entry: FY2021-Q2.
No other company in this theme has enough history to compare yet.
- FY2021-Q2Removed from the scope of equity-method accounting following the transfer of the entire equity interestAnnual report
「Shanghai Lichi Medical Technology Co., Ltd., formerly an equity-method affiliate, was removed from the scope of equity-method accounting from the second quarter of the current consolidated fiscal year because the company transferred its entire equity interest.」
The company transferred its entire equity interest in Shanghai Lichi Medical Technology Co., Ltd. and removed it from the scope of equity-method accounting from the second quarter of the current consolidated fiscal year. - FY2021-Q1Updated first-quarter equity-method investment lossAnnual report
「Equity-method investment loss 13」
In connection with its equity-method investees, the company recognized an equity-method investment loss of ¥13 million for the three months ended the first quarter of the current consolidated fiscal year. - FY2020Updated full-year equity-method investment lossAnnual report
「Equity-method investment loss 21,042」
The company disclosed a full-year equity-method investment loss of ¥21.042 million relating to its equity-method affiliate. - FY2020-Q3Updated third-quarter equity-method investment lossAnnual report
「Equity-method investment loss 17,306」
The company disclosed an equity-method investment loss of ¥17.306 million for the nine months ended the third quarter of the current consolidated fiscal year. - FY2020-Q2Updated second-quarter equity-method investment lossAnnual report
「Equity-method investment loss 8,919」
In connection with its equity-method investees, the company recognized an equity-method investment loss of ¥8.919 million for the six months ended the second quarter of the current consolidated fiscal year. - FY2020-Q1Recognition of Equity-Method Investment LossAnnual report
「Equity-method investment loss 3,728」
In connection with the application of the equity method to Shanghai Lichi Medical Technology Co., Ltd. and other entities, the company recognized an equity-method investment loss of ¥3.728 million in non-operating expenses. - FY2019-Q3First statedAnnual report
「Beginning in the third quarter of the current consolidated fiscal year, Shanghai Lichi Medical Technology Co., Ltd., an affiliate in which the company newly acquired an equity interest, was included within the scope of equity-method accounting.」
The company stated that it newly acquired an equity interest in Shanghai Lichi Medical Technology Co., Ltd. and included it within the scope of equity-method accounting from the third quarter of the current consolidated fiscal year.